Ian M. Graham
#161,076
Most Influential Person Now
Ian M. Graham's AcademicInfluence.com Rankings
Ian M. Grahammedical Degrees
Medical
#3242
World Rank
#3701
Historical Rank
Cardiology
#336
World Rank
#347
Historical Rank
Download Badge
Medical
Why Is Ian M. Graham Influential?
(Suggest an Edit or Addition)Ian M. Graham's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012) (6922)
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. (2003) (4909)
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) (3648)
- [ESC/EAS Guidelines for the management of dyslipidaemias]. (2011) (3612)
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (3071)
- European guidelines on cardiovascular disease and prevention in clinical practice. (2003) (2501)
- European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). (2003) (2476)
- Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. (1997) (1982)
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016) (1974)
- [2016 European Guidelines on cardiovascular disease prevention in clinical practice]. (2016) (1881)
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
- Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. (1998) (1370)
- Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) (2007) (1141)
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (1103)
- Prevention of coronary heart disease in clinical practice (1994) (1063)
- Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) (2007) (1040)
- European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. (2004) (1028)
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary. (2007) (965)
- Low-density lipoproteins cause atherosclerotic cardiovascular disease (2018) (936)
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit (2007) (911)
- [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. (2013) (876)
- Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. (1998) (872)
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit (2007) (869)
- European guidelines on cardiovascular disease prevention in clinical practice: full text (2005) (840)
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention (2016) (657)
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) (630)
- Expert position paper on air pollution and cardiovascular disease. (2015) (597)
- 'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. (2011) (596)
- European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) (2003) (592)
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
- Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. (1994) (519)
- Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. (1998) (513)
- World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions (2019) (423)
- EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (ENDING). FOURTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (2004) (412)
- Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. (2009) (408)
- Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. (2010) (382)
- Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. (2014) (310)
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2011) (290)
- Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. (1996) (254)
- Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future? (2010) (228)
- Homocysteine in Health and Disease (1999) (224)
- HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. (2009) (215)
- European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). (2004) (212)
- Plasma Total Cysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project (2001) (209)
- Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. (2018) (202)
- Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. (1998) (200)
- SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. (2021) (200)
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia (2018) (183)
- Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (2016) (170)
- Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg (2008) (145)
- Cardiovascular risk estimation in older persons: SCORE O.P. (2016) (136)
- Low Circulating Folate and Vitamin B 6 Concentrations Risk Factors for Stroke, Peripheral Vascular Disease, and Coronary Artery Disease (1998) (132)
- Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. (2000) (129)
- Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators (2011) (122)
- Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology* (2019) (122)
- How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators (2009) (121)
- Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. (2015) (121)
- Smoking and plasma homocysteine (2002) (116)
- Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. (2019) (115)
- Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies (2009) (113)
- European Society of Cardiology: cardiovascular disease statistics 2021. (2022) (113)
- Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology (2006) (109)
- Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality (2012) (96)
- Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. (2017) (96)
- Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. (1994) (91)
- Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). (2007) (87)
- Sex differences in risk factor management of coronary heart disease across three regions (2017) (87)
- SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. (2021) (83)
- [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. (2016) (83)
- Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. (1999) (79)
- Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group. (1999) (79)
- Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies (2018) (78)
- Challenges in secondary prevention after acute myocardial infarction: A call for action (2016) (74)
- Homocysteine Metabolism: From Basic Science to Clinical Medicine (1997) (72)
- Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. (2000) (69)
- Cardiovascular risk age: concepts and practicalities (2012) (67)
- LOW CONCENTRATIONS, RISK FACTORS FOR STROKE, PERIPHERAL VASCULAR DISEASE, AND CORONARY ARTERY DISEASE (1998) (64)
- [Calibrating the SCORE cardiovascular risk chart for use in Spain]. (2007) (64)
- Vitamins, Homocysteine and Cardiovascular Risk (2002) (62)
- Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. (2003) (59)
- The Association of Plasma Cysteine and γ‐Glutamyltransferase With BMI and Obesity (2009) (55)
- Challenges in secondary prevention after acute myocardial infarction: A call for action (2017) (55)
- The role of folic acid in the prevention of cardiovascular disease (2000) (54)
- The association of fasting plasma sulfur-containing compounds with BMI, serum lipids and apolipoproteins. (2012) (54)
- Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries (2016) (44)
- Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators (2013) (43)
- Consumption of dairy product and its association with total and cause specific mortality - A population-based cohort study and meta-analysis. (2019) (42)
- Task Force Report Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention 1,2 (1998) (41)
- Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques (2012) (41)
- Simplifying cardiovascular risk estimation using resting heart rate. (2010) (41)
- Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? (1993) (40)
- Challenges in secondary prevention after acute myocardial infarction: A call for action (2017) (35)
- Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence? (2009) (34)
- [Prevention of coronary disease in clinical practice. Recommendations of the Task-Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. (1995) (34)
- New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers (2005) (34)
- Homocysteine increases the risk associated with hyperlipidaemia (2009) (32)
- The importance of total cardiovascular risk assessment in clinical practice (2006) (32)
- Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories. (2013) (32)
- Thermolabile MTHFR genotype and retinal vascular occlusive disease (2001) (32)
- An evaluation of the performance of SCORE Sweden 2015 in estimating cardiovascular risk (2017) (30)
- Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. (1998) (30)
- Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy (2012) (29)
- Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA) (2015) (28)
- Assessment of Cardiovascular Risk (2010) (27)
- Guidelines on cardiovascular disease prevention in clinical practice: the European perspective (2005) (24)
- SURF – SUrvey of Risk Factor management: first report of an international audit (2014) (22)
- Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)) (2019) (19)
- Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. (2018) (19)
- Homocysteine as a risk factor for cardiovascular disease. (1991) (19)
- Current guidelines on prevention with a focus on dyslipidemias. (2017) (18)
- Dyslipidemia therapy update: the importance of full lipid profile assessment (2009) (17)
- Do novel biomarkers add to existing scores of total cardiovascular risk? (2012) (17)
- Homocysteine as a Risk Factor for Coronary Artery Disease (1995) (17)
- Heart attacks and homocysteine (1996) (17)
- New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk (2018) (17)
- Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement (2022) (17)
- von Willebrand factor in CHD and stroke: Relationships and therapeutic implications (2007) (16)
- Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis (2017) (16)
- Optimising implementation of European guidelines on cardiovascular disease prevention in clinical practice: what is needed? (2020) (16)
- Homocysteine and Vascular Disease: Nature or Nurture? (1998) (16)
- Total cardiovascular disease risk assessment: a review (2011) (14)
- Adverse Lifestyle Trends Counter Improvements in Cardiovascular Risk Factor Management in Coronary Patients. (2015) (13)
- Risks in estimating risk. (2014) (12)
- A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. (2012) (12)
- Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. (2021) (11)
- [European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice]. (2004) (11)
- Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit (2021) (11)
- Improvement in the estimation of cardiovascular risk by carotid intima-medial thickness: A report from the Dublin Cardiohealth station study (2015) (11)
- Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. (2020) (11)
- New prospects for PCSK9 inhibition? (2018) (10)
- Genes, greens, and homocysteine. (1996) (10)
- National perspective of acute coronary care in the Republic of Ireland. (1995) (9)
- The Detection of Heterozygous Familial Hypercholesterolemia in Ireland (2012) (9)
- Risk stratification and risk assessment (2015) (9)
- Guidelines on CVD prevention: confusing or complementary? (2013) (9)
- Integrin αIIbβ3 exists in an activated state in subjects with elevated plasma homocysteine levels (2011) (9)
- Prevention of cardiovascular disease: new guidelines, new tools, but challenges remain (2014) (9)
- European Society of Cardiology: cardiovascular disease statistics 2021. (2022) (8)
- Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. (2017) (8)
- Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (7)
- Body mass index determines the response of plasma sulfur amino acids to methionine loading. (2020) (6)
- Quality assurance and the need to evaluate interventions and audit programme outcomes (2017) (6)
- ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (6)
- Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (6)
- What impact will current trial data have on future guideline recommendations? (2005) (6)
- Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts? (2010) (6)
- An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. (2021) (5)
- Communicating risk—coronary risk scores (2003) (5)
- What is my risk of developing cardiovascular disease? (2009) (5)
- The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia (2011) (5)
- [Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology (ESC), European Atherosclerosis Society (EAS) and European Society of Hypertension (ESH)]. (1995) (5)
- [European practice guidelines on prevention of cardiovascular diseases: executive summary]. (2008) (4)
- Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground? (2017) (4)
- Optimising implementation of European guidelines on cardiovascular disease prevention in clinical practice: what is needed? (2020) (4)
- Diagnosing coronary artery disease--the Diamond and Forrester model revisited. (2011) (4)
- Determinants of coronary artery disease risk factor management across three world regions (2019) (4)
- Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm (2022) (3)
- [The prevention of coronary disease in clinical practice. The recommendations of the Second Joint Task Force of European Societies on the Prevention of Coronary Pathology. Società Europea di Cardiologia, Società Europea dell'Aterosclerosi, Società Europea dell'Ipertensione]. (2000) (3)
- ‘I’m just short for my weight, doctor’: body weight and risk (2011) (3)
- Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. (2012) (3)
- THE EFFECT OF QUERCETIN ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2016) (3)
- HeartScore predicts surrogate markers of cardiovascular disease in individuals aged below 40 years (2009) (3)
- Homocysteine and Vascular Disease: The European Concerted Action Project (1997) (3)
- A Global Analysis of Associations between Fine Particle Air Pollution and Cardiovascular Risk Factors: Feasibility Study on Data Linkage (2020) (2)
- [Prevention of coronary disease in clinical practice: summary for clinicians]. (1996) (2)
- Estimation of ten-year risk of combined fatal and non fatal cardiovascular events: the SCOREplus study (2013) (2)
- Chapter 3 Risk estimation systems in clinical use: SCORE, HeartScore, Framingham, PROCAM, ASSIGN, and QRISK (2011) (2)
- Principles of prevention of cardiovascular disease: Reply (2004) (2)
- Homocysteine and cardiovascular disease: time to routinely screen and treat? (2003) (2)
- [Prevention of coronary disease in clinical practice. Guidelines of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. (1996) (2)
- [Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. (1996) (1)
- Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis in a large international audit (2020) (1)
- The benefit of lowering cholesterol:Relative risk can beabsolutely misleading! (1998) (1)
- Estimating risk of cardiovascular disease in Eastern Europe. (2020) (1)
- [Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, The European Atherosclerosis Society and the European Hypertension Society. A short overview for general practitioners]. (1996) (1)
- Survey of cardiovascular disease and risk factor management in patients with rheumatoid arthritis across 5 world regions: results from the SURF-RA (2020) (1)
- European guidelines regarding the prevention of cardiovascular disease in clinical practice: a shorter version (2008) (1)
- SURF- a simple international audit of cardiovascular risk factor management (2013) (1)
- Whither cardiovascular risk prediction? (2005) (1)
- 1.W04.4 Homocysteinaemia as a risk factor for cardiovascular disease (1997) (1)
- New Way to “SCORE” Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines (2022) (1)
- New Way to “SCORE” Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines (2022) (1)
- GuidelinesESC/EAS Guidelines for the Management of Dyslipidaemias (2013) (0)
- Cardiovascular risk estimation at the individual level (2018) (0)
- Abstract 3990: Asymmetric Dimethylarginine Predicts Fatal and Non-Fatal Myocardial Infarction and Stroke in Women Independently of Homocysteine and Traditional Risk Factors: 24 Year Follow Up of the Population Study of Women in Gothenburg (2006) (0)
- Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network (1998) (0)
- Survey of risk factors in coronary heart disease (SURF CHD) II: rationale, methods for a novel recruitment strategy and preliminary results (2021) (0)
- Guidelines on CVD prevention: confusing or complementary? (2013) (0)
- Risk factor recording and management in coronary heart disease patients from 32 countries: SURF CHD II (2022) (0)
- Genetic Variants Related to Combined Exposure to both Lower Low- Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA Network Open, E1-E11 (2019) (0)
- Combined Exposure to both Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA (2019) (0)
- [Spanish adaptation of the European guidelines on cardiovascular prevention (and II)]. (2004) (0)
- [Prevention of coronary disease in clinical practice. Guidelines of the working group of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. (1995) (0)
- Evidence for Preventing Cardiovascular Disease (2015) (0)
- Is elevated resting heart rate an independent predictor of cardiovascular disease? A report from the National FINRISK Study (2014) (0)
- European CHD risk databases (1999) (0)
- Re: Editorial: Thresholds for normal blood pressure and serum cholesterol. BMJ 2005;330:1461-2 (2017) (0)
- SAT0091 SURVEY OF CARDIOVASCULAR DISEASE AND RISK FACTOR MANAGEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACROSS 5 WORLD REGIONS: RESULTS FROM THE SURF-RA (2020) (0)
- Risk factor management at the level of the individual using lifestyle changes (2018) (0)
- Homocysteine, hypertension and nutritional factors (1996) (0)
- Self reported diabetes predicts risk of cardiovascular death differently in men and women in high risk European countries: the score project (2006) (0)
- Examining the gap between evidence based guidelines and clinical practice in lipid modification in adults at high risk of cardiovascular disease mortality: evidence from an Irish cohort (2014) (0)
- Re-evaluation Rose: Comparative benefits of the population and high-risk preventive strategies (2009) (0)
- What is the place of new risk markers in the prediction of cardiovascular disease (2011) (0)
- P5417Consumption of dairy product and its association with total and cause specific mortality - A population-based cohort study and meta-analysis (2018) (0)
- Can incorporation of resting heart rate improve risk estimation systems (2014) (0)
- The epidemiology of cardiovascular disease (2021) (0)
- Management of dyslipidaemia and hypertension in patients with rheumatoid arthritis in 19 countries (2020) (0)
- Working group on epidemiology & prevention of the european society of cardiology (1998) (0)
- the Republic of Ireland . National perspective of acute coronary care in (2003) (0)
- THU0123 DIABETES MELLITUS AND CARDIOVASCULAR RISK MANAGEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A LARGE INTERNATIONAL AUDIT (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ian M. Graham?
Ian M. Graham is affiliated with the following schools:
